Biological
Donaperminogene seltoplasmid clinical trials
Also written VM202.
- studies test it
- 12
- open now
- 0
- in phase 3
- 1
- first study started
- 2007
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
12 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2010 | 2 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 10
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 2
Helixmith Co., Ltd. (10) · Northwestern University (1) · Brigham and Women's Hospital (1)
Studies
Open first, then newest update. How each study uses donaperminogene seltoplasmid is read from its arms, and is right about nine times in ten.
Testing it · 12
- Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES TrialWithdrawnPhase 2Brigham and Women's HospitalNCT04087941Written as VM-202
- Phase 3 Gene Therapy for Painful Diabetic NeuropathyCompletedPhase 3Helixmith Co., Ltd.NCT02427464Written as Engensis (VM202)
- Safety and Efficacy Study Using Gene Therapy for Critical Limb IschemiaCompletedPhase 2Helixmith Co., Ltd.NCT01064440Written as Low Dose VM202
- The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)CompletedPhase 1/2Helixmith Co., Ltd.NCT05361031Written as Engensis (VM202)
- Safety Study of VM202 to Treat Amyotrophic Lateral SclerosisCompletedPhase 1/2Helixmith Co., Ltd.NCT02039401Written as VM202
- Gene Therapy for Painful Diabetic NeuropathyCompletedPhase 1/2Helixmith Co., Ltd.NCT01002235Written as VM202
- Safety and Efficacy Study for the Treatment of Painful Diabetic NeuropathyCompletedPhase 2Helixmith Co., Ltd.NCT01475786Written as Low Dose: 16 mg Engensis (VM202)
- Safety Study of Gene Therapy in Treating Critical Leg IschemiaCompletedPhase 1Helixmith Co., Ltd.NCT00696124Written as VM202 2 mg
- Safety Study of Gene Therapy for Ischemic Heart Disease in KoreaCompletedPhase 1/2Helixmith Co., Ltd.NCT01422772Written as VM202-0.5 mg
- Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in KoreaWithdrawnPhase 2Helixmith Co., Ltd.NCT03404024Written as Stage 1-Middle dose VM202RY
- Gene Therapy for the Treatment of Chronic Stable AnginaWithdrawnPhase 1/2Helixmith Co., Ltd.NCT01002495Written as VM202
- Hepatocyte Growth Factor to Improve Functioning in PADCompletedPhase 2Northwestern UniversityNCT03363165Written as VM202
Codes
What other systems call donaperminogene seltoplasmid · ClinicalTrials.gg INT015138
- UNII (FDA) 5WL65F3KCBDONAPERMINOGENE SELTOPLASMIDOne source FDA
- NCI Thesaurus C166868Donaperminogene SeltoplasmidOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5WL65F3KCB | DONAPERMINOGENE SELTOPLASMID | One source FDA |
| NCI Thesaurus | C166868 | Donaperminogene Seltoplasmid | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.